300003 乐普医疗
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,672,061-3.70%6,482,7326,103,2697,979,89910,609,442
减:营业总成本1,409,7886.65%5,250,5315,522,1186,354,8877,926,747
    其中:营业成本634,8091.63%2,333,2612,387,6472,853,2863,983,286
               财务费用138,110314.97%160,94642,24484,92992,578
               资产减值损失(792)-65.12%(149,398)(287,867)(165,092)(37,953)
公允价值变动收益(133)-114.21%1,5533893,0924,420
投资收益739-96.24%49,445(89,713)(16,533)(75,335)
    其中:对联营企业和合营企业的投资收益(1,046)-105.32%62,024(65,950)(24,361)(90,833)
营业利润264,526-43.53%1,220,070253,1391,547,2152,623,139
利润总额258,789-44.34%1,216,078225,7611,554,4982,611,782
减:所得税费用35,595-59.41%197,07528,467262,147365,726
净利润223,193-40.83%1,019,004197,2941,292,3512,246,055
减:非控股权益(23,621)1,681.60%56,997(49,644)34,15142,276
股东净利润246,814-34.80%962,006246,9381,258,2002,203,779

市场价值指针
每股收益 (元) *0.134-34.78%0.5220.1340.6761.223
每股派息 (元) *----0.3260.2770.3310.341
每股净资产 (元) *8.9188.90%8.6267.9698.3817.940
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容